Polaryx Therapeutics, Inc. (PLYX) stock
Close on Nov 17, 2026Market cap $79.75MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $79.75M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 10.48
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$8.75M
- EPS, diluted
- -$0.18
- Book value per share
- $0.15
- Diluted shares
- 50M
Trading
- Previous close
- $1.67
- Open
- $1.62
- Day's range
- $1.56 – $1.67
- Volume
- 30,656
- Average volume (20 days)
- 22,290
- 52-week range
- $1.56 – $48.91
- RSI (14 days)
- 34.5
- Volatility (1 year)
- 186.6%
- Relative volume
- 0.52×
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | PLYX | S&P 500 | Difference | PLYX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -14.9% | -4.0% | −10.9 pts | ||
| 3 months | -23.8% | -5.0% | −18.8 pts |
Three years at a glance
Fiscal years 2023 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases Polaryx Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
About Polaryx Therapeutics
Pharmaceutical Preparations
Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops treatments for rare pediatric lysosomal storage disorders. Its therapeutic pipeline comprises oral small molecule candidates and gene therapies targeting underlying cellular dysfunction and neuroinflammation. The company's lead product candidate is PLX-200, a reformulated oral solution targeting neuronal ceroid lipofuscinosis subtypes CLN2 and CLN3, Krabbe disease, and Sandhoff disease. Other programs include PLX-300, a small molecule in preclinical evaluation, PLX-100, an oral combination therapy, and PLX-400, an early-stage gene therapy. The company operates in the lysosomal storage disorders segment, developing therapies primarily for pediatric patients diagnosed with fatal genetic metabolic conditions.
Company profile, executives and historyPolaryx Therapeutics stock: common questions
What is Polaryx Therapeutics's stock price?
PLYX closed at $1.60 on Nov 17, 2026, down 4.19% on the day. Over the past 52 weeks it traded between $1.56 and $48.91.
What is Polaryx Therapeutics's market cap?
Polaryx Therapeutics was worth $79.75M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is PLYX's P/E ratio?
Polaryx Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.18), so it has no meaningful P/E ratio.
Does Polaryx Therapeutics pay a dividend?
No. Polaryx Therapeutics has not paid a cash dividend over the last twelve months.
How many PLYX shares are sold short?
0M shares were sold short at the latest FINRA report, 0.59% of the float, or 6.5 days of average trading volume.
Who are Polaryx Therapeutics's competitors?
Companies most similar to Polaryx Therapeutics by business, industry and size include LRMR, GRCE, KTTA, AMLX, PRAX.
See a number that looks wrong?